A model too far

Journal of the National Cancer Institute

Volumn 106, Issue 2, 2014, Pages

  Freidlin, Boris ^a   Korn, Edward L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BLOOD; COMPUTER SIMULATION; FEMALE; HUMAN; MALE; MASS SCREENING; METHODOLOGY; NOMOGRAM; NOTE; PROSTATE TUMOR;

COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MASS SCREENING; NOMOGRAMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893862537     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt368     Document Type: Editorial

References (11)

1. Dunn BK, Srivastava S, Kramer BS. The word "cancer": how language can corrupt thought: antiquated nomenclature is misleading and needs to be revised. BMJ. 2013;347(7925):f5328.
2. Kramer BS, Croswell JM. Cancer screening: the clash of science and intuition. Ann Rev Med. 2009;60:125-137.
3. Gulati R, Inoue L Y T, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst. 2013; XX(XX): XXX-XXX.
4. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
5. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns-getting past uninformative persuasion. New Engl J Med. 2012;367(18):1677-1679.
6. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158(3):145-153.
7. Moyer VA. Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134.
8. Heijnsdijk E A M, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. New Engl J Med. 2012;367(7):595-605.
9. Etzioni R, Gulati R, Cooperberg M, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening. Med Care. 2013;51(4):295-300.
10. Melnikow J, Lefevre M, Wilt T, Moyer V. Counterpoint: randomized trials provide the strongest evidence for clinical guidelines: the US Preventive Services Task Force and prostate cancer screening. Med Care. 2013;51(4):301-303.
11. Brawley OW. Prostate cancer screening: what we know, don't know, and believe. Ann Intern Med. 2012;157(2):135-136.